

Eur J Clin Microbiol Infect Dis (2014) 33:1019–1027
DOI 10.1007/s10096-013-2040-4

ARTICLE

Seroprevalence of campylobacteriosis and relevant post-infectious sequelae

A. E. Zautner · C. Johann · A. Strubel · C. Busse ·
A. M. Tareen · W. O. Masanta · R. Lugert ·
R. Schmidt-Ott · U. Groß

Received: 12 September 2013 / Accepted: 16 December 2013 / Published online: 12 January 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract Post-infectious sequelae such as Guillain Barré syndrome (GBS), reactive arthritis (RA), and inflammatory bowel disease (IBD) may arise as a consequence of acute *Campylobacter*-enteritis (AE). However, reliable seroprevalence data of *Campylobacter*-associated sequelae has not been established. The objectives of this study were, first, to identify the most specific and sensitive test antigen in an optimized ELISA assay for diagnosing a previous *Campylobacter*-infection and, second, to compare the prevalence of anti-*Campylobacter* antibodies in cohorts of healthy blood donors (BD), AE, GBS, RA, and IBD patients with antibodies against known GBS, RA and IBD triggering pathogens. Optimized ELISAs of single and combined *Campylobacter*-proteins OMP18 and P39 as antigens were prepared and sera from AE, GBS, RA and IBD patients and BD were tested for *Campylobacter*-specific IgA and IgG antibodies. The results were compared with MIKROGEN™-recomLine *Campylobacter* IgA/IgG and whole cell lysate-immunoblot. Antibodies specific for *Helicobacter pylori*, *Mycoplasma pneumoniae*, *Yersinia enterocolitica*, and *Borrelia afzelii* were tested with commercial immunoblots. ROC plot analysis revealed AUC maxima in the combination of OMP18 and P39

for IgA and in the P39-antigen for IgG. As a result, 34–49 % GBS cases, 44–62 % RA cases and 23–40 % IBD cases were associated with *Campylobacter*-infection. These data show that *Campylobacter*-seropositivity in these patient groups is significantly higher than other triggering pathogens suggesting that it plays an important role in development of GBS and RA, and supports the hypothesis that recurrent acute campylobacteriosis triggers IBD.

Introduction

Members of genus *Campylobacter* are Gram-negative and microaerophilic bacteria that invade the gastrointestinal tract of humans causing campylobacteriosis whose clinical symptoms include bloody or watery diarrhea, abdominal pain, fever, headache, nausea and vomiting. Although this acute enteritis is self-limiting, post-infectious sequelae GBS, RA and IBD can arise after recovery [1–3]. Recently, *C. jejuni* has been found to be the leading cause of bacterial gastroenteritis worldwide [4, 5], which has led to renewed interest in quantifying the seroprevalence of *Campylobacter*-specific antibodies in the rising cases of GBS, RA and IBD as post-infectious sequelae.

Recent studies have shown GBS an autoimmune disorder in which the body's immune system attacks GM-gangliosides in the central nervous system leading to acute neuromuscular paralysis and consecutive muscle weakness succeeding campylobacteriosis [6]. Furthermore, cytomegaloviruses (CMV), Epstein-Barr viruses (EBV) and *Mycoplasma pneumoniae* have been shown to trigger GBS [6]. Presently, four common types of GBS are recognized *vis-à-vis* the Miller Fisher syndrome (MFS), the acute motor axonal neuropathy (AMAN), the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and the acute motor-sensory axonal neuropathy (AMSAN) [6]. Importantly,

A. E. Zautner · C. Johann · A. M. Tareen · W. O. Masanta ·
R. Lugert · R. Schmidt-Ott · U. Groß
Institut für Medizinische Mikrobiologie, Universitätsmedizin
Göttingen, Kreuzberggring 57, 37075 Göttingen, Germany

A. E. Zautner (✉) · W. O. Masanta
UMG-Labor, Institut für Klinische Chemie/Zentrallabor,
Universitätsmedizin Göttingen, Göttingen, Germany
e-mail: azautne@gwdg.de

A. Strubel · C. Busse
Sekisui Virotech GmbH, Rüsselsheim, Germany

Present Address:
R. Schmidt-Ott
GlaxoSmithKlineVaccines, Wavre, Belgium

Campylobacter has been linked to trigger MFS, AMAN, and AMSAN [6].

Similarly, RA has been shown to develop after campylobacteriosis [7–9]. Like in GBS, other pathogens including *Salmonella enterica*, *Shigella dysenteriae*, *Yersinia enterocolitica*, *Yersinia pseudotuberculosis*, and *Chlamydia trachomatis* have been implicated in triggering RA [7]. In previous studies the incidence of RA in acute campylobacteriosis patients was found to range from 1 to 7 % [7, 10]. However, seroprevalence data in RA patients, with an acute flare up of arthritis has not been estimated so far.

Equivalently, epidemiologic, ecologic and genetic studies have associated the pathogenesis of IBD, a strictly gastrointestinal tract immunological disorder, with interplay between *C. jejuni*, host genetic susceptibility, recurrent AE, and commensal microflora [11–15]. It has been revealed that host genetics influences the diversity and load of commensal microflora. However, slight alteration in diversity and loads of members of the commensal microflora of phyla Firmicutes and Bacteroidetes due to diet and other unknown agents, promotes intestinal epithelial invasion by *C. jejuni* leading to development of IBD [15–17].

The *Campylobacter* literature shows inconsistency in the frequency of previous *Campylobacter* infections in these sequelae. As a consequence, there is under- or over-estimation of *Campylobacter*-triggered post infectious sequelae. This has been attributed to lack of reliable serological assays for detecting previous *Campylobacter* infections due to poor standardization and cross-reactivity to other pathogens including *Helicobacter* spp., *Arcobacter* spp., *Salmonella* spp., *Legionella* spp., *Yersinia* spp., and *Corynebacterium* spp. [18–20].

Recently, we reported on a *Campylobacter* ELISA with 91.9 % sensitivity and 99.0 % specificity that is reliable for detecting previous *Campylobacter* antibodies in healthy individuals (BD), AE-patients and GBS-patients [21]. This assay is based on a combination of two purified *Campylobacter* antigens, namely, OMP18 and P39 [22]. However, the most specific and sensitive antigen or antigen combination for the detection of previous *Campylobacter* infection in a particular post-infectious sequel remains unknown. Furthermore, the ability of antigens OMP18 and P39 to diagnose previous *Campylobacter* infection in RA-patients and IBD-patients is also unknown. Clearly, knowledge of the specificity and sensitivity of antigens OMP18 and P39 is important for continuous development of reliable assays for detecting previous *Campylobacter* infections in a particular post-infectious sequel.

In the present study, we investigated the most specific and sensitive antigen between OMP18, P39 and combined OMP18+P39 for detecting *Campylobacter* specific antibodies in AE-patients and patients of each named post-infectious sequel; we tested sensitivity and specificity of optimized

OMP18 and P39 ELISA in detecting prior *Campylobacter* infections by comparing its results with those of antigens MOMP, PEB1, PEB2, PEB4, OMP18, and P39 embedded in MIKROGENTM-recomLine *Campylobacter* IgA/IgG blot and of a whole cell lysate immunoblot [23]; we used the optimized OMP18+P39 and P39 ELISA to determine the seroprevalence of *Campylobacter* specific IgA and IgG antibodies in BD, AE, GBS, RA, and IBD respectively; we tested BD, AE, GBS, RA, and IBD sera for the presence of antibodies against *Helicobacter pylori* and *Yersinia enterocolitica* which are known to cross-react with *Campylobacter* antigens [24] and *Mycoplasma pneumonia* and *Borrelia afzelii* that cause similar clinical symptoms as those observed in campylobacteriosis associated post-infectious sequelae.

Materials and methods

Sera tested in the study

Sera tested in this study were collected from 91 GBS patients, 60 AE patients, 50 RA patients, 39 IBD patients and 80 BD.

The GBS cohort comprised of three sera from confirmed MFS patients and the remaining 88 were AMAN, AIDP and AMSAN suspected cases, which had not been clinically distinguished. Mean age of the patients was 61.2 ± 17.1 years; the age median was 66.0 ± 13.6 years and the proportion of male to female patients was 46.8 %:53.2 %. The sera of patients with acute diarrhea and a *Campylobacter*-positive stool culture were included as positive control. The mean age of AE patients was 47.5 ± 24.3 years, the age median was 51.0 ± 21.1 years, and the proportion of male to female patients was 59.3 %:40.7 %. The mean age of RA patients was 39.7 ± 22.0 years, the age median was 43.5 ± 19.5 years and the proportion of male to female patients was 48.0 %:52.0 %. The serum samples were collected at an acute flare-up stage of arthritis. The IBD patient group's age mean was 37.3 ± 21.5 years, the age median was 38 ± 18.2 years, and the proportion of male to female patients was 40.7 %:59.3 %. The mean age of BDs was 39.2 ± 21.3 years, the age median was 42.2 ± 20.1 years, and the proportion of male to female patients was 48.4 %:52.6 %. BD sera were taken in July 2011 to serve as control group to estimate the seroprevalence of *Campylobacter*-specific antibodies in healthy individuals. All patients had been hospitalized in the University Medical Center Göttingen from 2001 to 2011 but there were no GBS cases in 2004 and 2005. All sera were stored at -80°C until testing.

Optimized ELISA assays

ELISA embedded with *C. jejuni* proteins P39 and OMP18 as antigens, singularly and combined, were prepared. Initially,

the recombinant proteins P39 and OMP18 were expressed and purified as described before [22]. Then both proteins were diluted in bicarbonate buffer (pH=8.4) to a final concentration of 3.0 µg/mL of P39 and 5.0 µg/mL of OMP18. NuncMaxiSorp® 96-well plates (Thermo Fisher Scientific Inc., Langensfeld, Germany) were coated with 100 µL protein solution of P39 or OMP18 or P39+OMP18 at room temperature overnight in a wet chamber. After the coating procedure, the plates were washed three times with phosphate-buffered saline (PBS). Thereafter the plates were blocked with 1.0 % BSA in PBS for one hour at room temperature followed by lyophilization. After lyophilization the plates were stored dry. The measurement procedure was performed as described before [22], but with some modifications. First, the patient sera were used at 1:100 dilutions. The secondary horseradish peroxidase-labeled goat anti-human IgA and IgG antibodies were used at a dilution of 1:4000 (anti-human IgA) and 1:50,000 (anti-human IgG; KPL, Gaithersburg, USA). Therewith, we significantly increased the amount of antigen used and decreased the concentration of the secondary antibody in order to achieve higher sensitivity than previously described [22]. Signal intensities above the cut-off value 10.0+1.0 Virotec units (VU=10*OD-sample/OD-Cut-Off) were considered as positive, below the cut-off value 10.0 – 1.0 VU were considered as negative, and in the range of cut-off value 10.0 +/- 1.0 VU were considered as borderline.

MIKROGEN-recomLine *Campylobacter* blot and whole cell lysate-immunoblot

AE and GBS patient and BD sera were tested on MIKROGEN-recomLine *Campylobacter* IgA/IgG blot and whole cell lysate-immunoblot. Analysis using the well-established recomLine*Campylobacter* IgA and IgG blot (MIKROGEN Diagnostik, Neuried, Germany) was done as recommended by the manufacturer. On the other hand, the whole cell-lysate (WCL) line-blot was prepared and measurement carried out as previously described [23]. The evaluation of the sera on the whole cell lysate-immunoblot was determined by their responses to PEB1, PEB2, PEB3 and PEB4 antigens [23].

Helicobacter, *Mycoplasma*, *Yersinia*, and *Borrelia* immunoblots

Helicobacter pylori LINE, *Mycoplasma pneumonia* LINE, *Yersinia enterocolitica* LINE, and *Borrelia* LINE Immunoblot assays (Sekisui Virotech GmbH, Rüsselsheim, Germany) were used for the detection of antibodies against *Helicobacter pylori*, *Mycoplasma pneumoniae*, *Yersinia enterocolitica*, and *Borrelia afzelii*, respectively. The prevalence of IgG and IgA antibodies against these pathogens was determined in all sera except against *B. afzelii* where only the prevalence of IgG was determined.

Statistical analyses

The χ^2 -test was used to test for significant differences. The obtained p-values are indicated as ‘*’ ($p>0.05$), ‘**’ ($p<0.05$), or ‘***’ ($p<0.001$) as shown in Table 2. Calculation of ROC curves and their comparison was performed using the ROC-Excel-Tool (ACOMED Statistik, Leipzig, Germany).


Results

Determination of OMP18, P39 and OMP18+P39 ROC AUC values during detection of *Campylobacter* specific antibodies in BD, AE, GBS, RA and IBD

Evaluation of OMP18, P39, and OMP18+P39 AUCs revealed that ELISA embedded with antigen combination OMP18+P39 has a significant advantage in *Campylobacter*-specific IgA detection as compared to ELISA embedded with OMP18 in AE sera ($p<0.05$; Fig. 1a), in GBS sera ($p<0.05$; Fig. 1b) and to ELISA embedded with antigen P39 tested with GBS sera ($p<0.05$; Fig. 1c). The comparison of AUCs for the detection of *Campylobacter*-specific IgG antibodies showed no significant differences between ELISAs embedded with OMP18, P39, and OMP18+P39 except AUC of ELISA embedded with P39 which was significantly larger as compared to AUC of ELISA embedded with OMP18+P39 ($p<0.05$; Fig. 1d) testing GBS sera. ROC AUCs of antigens MOMP, PEB1, PEB2, and PEB4 and WCL were significantly smaller compared to antigens OMP18, P39 and OMP18+P39 for both IgA and IgG (results not shown).

Table 1 lists sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of tested individual antigens OMP18, P39, MOMP, PEB1, PEB2, and PEB4 as well as the combined antigens OMP18+P39, and whole cell lysate estimated on sera of stool culture positive campylobacteriosis patients and healthy blood donors. With a specificity of approximately 90 % the OMP18, P39 and OMP18+P39-based ELISAs showed a sensitivity of 57.1 %, 40.7 %, and 38.9 %, respectively, when tested for IgA and 51.9 %, 57.4 %, and 47.3 %, respectively, when tested for IgG. OMP18 and P39 tested on MIKROGEN recomLine blot demonstrated ≈ 10 % increase in specificity and ≈ 15 % decrease in sensitivity. In contrast, antigens MOMP, PEB1, PEB2, and PEB4 tested on MIKROGEN recomLine blot showed 0.0–18.3 % sensitivity when specificity of nearly 100 % was achieved. The selection of the cut-off is based on optical density raw data in a non-parametric approach. As shown by the calculated MIKROGEN evaluation index (Table 1), MOMP, PEB1, PEB2, and PEB4 resulted in 8 % increase in the specificity of IgA detection as compared to OMP18+P39 ELISA. The sensitivity and specificity of IgG antibody detection was reduced by 7 % as compared to that of

Fig. 1 Receiver operating characteristic (ROC) curves comparing the antigens/antigen-combinations P18, P39, and P39+P18 for the detection of anti-*Campylobacter* antibodies. **a** Sera of culture-positive acute *Campylobacter*-enteritis patients tested for anti-*Campylobacter* IgA. **b**, **c** Sera of GBS patients tested for anti-*Campylobacter* IgA. **d** GBS patients tested for anti-*Campylobacter* IgG. AUC area under the curve, SE standard error, 0.95 low./upp. CL 0.95 lower and upper confidence limits, *p* *p*-value



P39 ELISA. The WCL-based blot showed a sensitivity of 28.6 % and a specificity of 96.2 % in the detection of IgA antibodies and a sensitivity of 48.6 % and a specificity of 83.8 % in the detection of IgG antibodies.

These results show that a line blot or an ELISA based on antigen P39 and OMP18 have the highest sensitivity and specificity. Also, incorporation of antigens PEB1, PEB2, PEB4, and MOMP into line blot does not significantly improve sensitivity or specificity (Table 1).

Evaluation of IgA, IgG and IgA/IgG reactivity in BD, AE, GBS, RA and IBD sera

OMP18+P39-based ELISA for detection of antibody IgA and P39-based ELISA for detection of antibody IgG were used to determine the *Campylobacter* seroprevalence in BD, AE, GBS, RA and IBD sera.

As shown in Table 2, the reactivity of IgA antibodies in BD sera was 9–12 %, in culture-positive AE sera 35–45 % ($p < 0.001$), in GBS sera 48–55 % ($p < 0.001$), in RA sera 34–40 % ($p < 0.05$) and in IBD sera it was 26–31 % ($p < 0.05$).

Campylobacter-specific IgA antibody prevalence was high in GBS followed by AE, RA and IBD sera in that order.

As shown in the same table, the P39-based prevalence of *Campylobacter*-specific IgG antibodies in BD was 9–17 %, in AE it was 52–62 %, in GBS 37–53 %, in RA 54–66 %, and in IBD it was 44–47 % ($p < 0.001$). *Campylobacter*-specific IgG antibody prevalence was high in RA sera followed by AE, IBD and GBS sera in that order.

Combined IgA/IgG reactivity was found to be 16–26 % in BD, 62–72 % in AE, 60–65 % in GBS, 70–78 % in RA and 49–56 % in IBD sera.

Comparison of *H. pylori*, *M. pneumoniae*, *Y. enterocolitica*, and *B. afzelii* specific antibody prevalences in AE, GBS, RA, IBD and BD sera

There was no significant difference in *H. pylori*-specific antibody-prevalence in AE, RA, and IBD patient sera compared to BD sera. However, antibody-prevalence of *H. pylori*-specific IgA in GBS sera was significantly higher (Table 2); 9–17 % anti-*Campylobacter* and anti-*Helicobacter* antibody

Table 1 Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) estimated on sera of stool culture positive campylobacteriosis patients and healthy blood donors

Antigen	Sensitivity [%]		Specificity [%]		PPV [%]		NPV [%]	
	IgA	IgG	IgA	IgG	IgA	IgG	IgA	IgG
OMP18 ELISA	57.1	51.9	90.5	90.8	82.1	79.4	73.6	73.4
P39 ELISA	40.7	57.4	90.9	90.5	75.9	81.6	68.6	74.4
OMP18+P39 ELISA	38.9	47.3	91.0	90.8	75.0	78.8	68.3	70.4
MOMP MG	18.3	3.3	100	96.3	100	40.0	62.0	57.0
PEB4 MG	16.7	3.3	100	98.8	100	66.7	61.5	57.7
PEB2 MG	3.3	1.7	100	100	100	100	57.9	57.6
PEB1 MG	0.0	1.7	100	97.5	-	33.3	57.1	56.9
OMP18 MG	41.7	36.7	100	98.8	100	95.7	69.6	67.5
P39 MG	41.7	45.0	98.8	86.3	96.2	71.0	69.3	67.6
Index MG	56.7	50.0	98.8	83.8	97.1	69.8	75.2	69.1
WCL	28.6	48.6	96.2	83.8	76.9	58.6	75.0	77.2

OMP18 outer membrane protein 18 kDa, P39 protein 39 kDa, MOMP major outer membrane protein, PEB1–4 periplasmic-binding proteins 1–4, Index MG numerical index for test evaluation that is the sum of the ascribed points of all positive antigens, i.e. bands with coloration more intense than the cut-off band, WCL whole cell lysate

double positive sera were found in all sera (AE, GBS, RA, IBD, and BD sera). See Table 3 for a particular group.

There was no significant difference in reactivity of anti-*M. pneumonia* IgA-antibodies in all sera. But there was a significant increase ($p<0.05$) in the reactivity of *M. pneumonia*-specific IgG in AE, RA, and IBD sera but not in GBS sera (Table 2); 16–23 % of all tested sera were positive for both anti-*Campylobacter* antibodies and anti-*M. pneumonia* antibodies (Table 3); 4 % of GBS sera that were negative for anti-*Campylobacter*-reactive antibodies showed both IgA and IgG antibodies reactive against *M. pneumonia*. The anti-*Campylobacter* antibody and anti-*M. pneumonia* antibody double-positive (IgA and IgG) rate was 23–33 % in GBS sera (results not shown).

The prevalence of *Y. enterocolitica*-reactive IgA antibodies significantly increased ($p<0.05$) in GBS, RA, AE, and IBD sera. *Y. enterocolitica*-reactive IgG antibodies significantly increased ($p<0.001$) in only RA sera. Also, 15–18 % (IgA), 8–11 % (IgG), and 23–35 % (IgA+IgG) of all tested sera were positive for both *Y. enterocolitica*- and *Campylobacter*-reactive antibodies (Table 3). Specifically, a significant increase of double-positive rate for IgA antibodies was 17–30 % in AE, 19–26 % in GBS and 18–26 % in RA sera. Increase of double-positive rate for IgG was 14–16 % in RA sera only. Anti-*Yersinia* antibodies (IgA/IgG) in *Campylobacter* antibody-negative sera were found in 3–18 %/3–5 % of AE, 12–19 %/7–9 % of GBS, 10–12 %/6–14 % of RA, and 5–10 %/8–13 % of IBD sera.

No significant difference in anti-*B. afzelii*-IgG antibody prevalence was observed between RA and BD sera. However, there was a significant increase ($p<0.05$) in the prevalence of anti-*B. afzelii*-IgG antibodies in AE, GBS, and IBD patients; 13–22 % of all tested sera were anti-*Campylobacter* IgA and IgG antibody and anti-*Borrelia* IgG antibody double positive (Table 3). This double-positive rate was significantly ($p<0.05$) above average in GBS patients (26–30 %) but below average in RA-patients (6 %) (results not shown).

Discussion

In a generation of seroprevalence data, antigen or antigen combination is decisive for the test concerned. Generally, the reactivity of the immunoglobulin classes IgA and IgG is determined in *Campylobacter* serodiagnostics because they have been found to have high sensitivity [25]. Immunoglobulin class IgM is rarely used because of its low sensitivity [23, 25]. Routine serodiagnostics of prior *C. jejuni*-infections is performed using an ELISA or an immunoblot with whole cell lysate or recombinant antigens [20, 23, 25]. Recombinant antigens including MOMP [26, 27], OMP18 [28], P39 [22], Cj0069 [20], and PEB 1, PEB 2, PEB 3, and PEB 4 [29] are used to detect *Campylobacter* specific antibodies. However, the sensitivity of OMP18 and P39 in relation to MOMP, PEB1, PEB2, PEB3 and PEB4 is unknown.

Therefore, one of the objectives of this study was to determine which antigen between OMP18, P39 and antigen combination (OMP18+P39) is the most sensitive and specific for detecting anti-*Campylobacter* antibodies in the diagnosis of acute campylobacteriosis and post-infectious sequelae. According to our data, an ELISA based on the combination of OMP18+P39 shows the ROC AUC maximum for IgA antibodies whereas an ELISA based on P39 alone exhibits the maximal ROC AUC for IgG antibodies. Antigens P39 and OMP18 as part of the MIKROGEN recomLine blot show almost the same values for sensitivity, specificity, PPV and NPV as those of antigens P39 and OMP18 being part of an ELISA. Therefore, it is evident that a line blot or an ELISA based only on antigens P39 and OMP18+P39 are the most sensitive and specific in detecting *Campylobacter*-specific antibodies in all patient groups. Additional detection of anti-MOMP, -PEB1, -PEB2, and -PEB4 immune reactivity does not significantly improve *Campylobacter* serology. Consequently, the testing of antibodies using these antigens in *Campylobacter* serology should be discouraged and testing of antibodies using P39 and OMP18+P39 encouraged.

In this study 16–26 % of healthy BD tested positive for both *Campylobacter*-specific IgA and IgG antibodies. The serum samples of the healthy blood donors were collected during a summer month in which the *Campylobacter*

Table 2 Seroprevalence of *Campylobacter* (using P18, P39 & P18&P39), *Helicobacter pylori*, *Mycoplasma pneumoniae*, *Yersinia enterocolitica*, and *Borrelia afzelii* in the different patient groups

Bacterium	<i>Campylobacter</i> -OMP18	<i>Campylobacter</i> -P39	<i>Campylobacter</i> -P18+P39	<i>Helicobacter pylori</i>	<i>Mycoplasma pneumoniae</i>	<i>Yersinia enterocolitica</i>	<i>Borrelia afzelii</i>
Ig class	IgA	IgG	IgA	IgG	IgA	IgG	IgG
BD	+ 9 % (7/80)	9 % (7/80)	9 % (7/80)	9 % (7/80)	9 % (7/80)	9 % (7/80)	9 % (7/80)
	± 8 % (6/80)	5 % (4/80)	4 % (3/80)	4 % (3/80)	1 % (1/80)	5 % (4/80)	1 % (1/80)
	- 84 % (67/80)	86 % (69/80)	88 % (70/80)	88 % (70/80)	90 % (66/80)	86 % (69/80)	90 % (72/80)
AE	+ 53 %*** (32/60)	45 %*** (27/60)	37 %*** (22/60)	3 %* (2/60)	3 %* (2/60)	25 %** (15/60)	22 %** (13/60)
	± 7 % (4/60)	13 % (8/60)	10 % (6/60)	7 % (4/60)	3 % (2/60)	5 % (3/60)	13 % (8/60)
	- 40 % (24/60)	42 % (25/60)	53 % (32/60)	90 % (54/60)	93 % (56/60)	70 % (42/60)	72 % (43/60)
GBS	+ 45 %*** (41/91)	26 %** (24/91)	35 %*** (32/91)	19 %** (17/91)	10 %* (9/91)	21 %* (19/91)	41 %*** (37/91)
	± 9 % (8/91)	15 % (14/91)	10 % (9/91)	7 % (6/91)	4 % (4/91)	8 % (7/91)	18 % (16/91)
	- 46 % (42/91)	58 % (53/91)	55 % (50/91)	75 % (68/91)	86 % (78/91)	71 % (65/91)	42 % (38/91)
RA	+ 40 %*** (20/50)	34 %** (17/50)	26 %*** (13/50)	8 %* (4/50)	6 %* (3/50)	36 %*** (18/50)	30 %*** (15/50)
	± 8 % (4/50)	14 % (7/50)	10 % (5/50)	2 % (1/50)	6 % (3/50)	8 % (4/50)	10 % (5/50)
	- 52 % (26/50)	52 % (26/50)	64 % (32/50)	90 % (45/50)	88 % (44/50)	56 % (28/50)	60 % (30/50)
IBD	+ 33 %** (13/39)	18 %* (7/39)	26 %*** (10/39)	5 %* (2/39)	3 %* (1/39)	5 %* (2/39)	26 %** (10/39)
	± 5 % (2/39)	13 % (5/39)	3 % (1/39)	18 % (7/39)	10 % (4/39)	8 % (3/39)	15 % (6/39)
	- 62 % (24/39)	69 % (27/39)	72 % (28/39)	77 % (30/39)	87 % (34/39)	87 % (34/39)	67 % (26/39)

AEacute campylobacteriosis (reference: stool culture), GBSGuillain-Barré-Syndrome, RAreactive arthritis, IBDinflammatory bowel disease (Morbus Crohn & ulcerative colitis); + positive, ± borderline, - negative.

Different significance levels in the comparison of a particular patient group with blood donors (BD) are indicated with ** ($p > 0.05$ = not significant), *** ($p < 0.05$ = significant), and **** ($p < 0.001$ = significant)

Table 3 Percentages and absolute numbers of *Campylobacter*-, *Helicobacter pylori*-, *Mycoplasma pneumoniae*-, *Yersinia enterocolitica*-, and *Borrelia afzelii*-positive tested (IgA and IgG) serum samples as well

Bacterium	<i>Campylobacter</i> IgA ⁺ or IgG ⁺	<i>Helicobacter pylori</i> IgA ⁺ or IgG ⁺	<i>Mycoplasma pneumoniae</i> IgA ⁺ or IgG ⁺	<i>Yersinia enterocolitica</i> IgA ⁺ or IgG ⁺	<i>Borrelia afzelii</i> IgG ⁺
<i>Campylobacter</i> IgA⁺ or IgG⁺	50–57 % (159–183)	9–17 % (28–53)	16–23 % (51–75)	23–35 % (75–112)	13–22 % (42–70)
<i>Helicobacter pylori</i> IgA⁺ or IgG⁺	9–17 % (28–53)	13–23 % (43–73)	4–11 % (13–34)	6–14 % (19–46)	5–11 % (15–35)
<i>Mycoplasma pneumoniae</i> IgA⁺ or IgG⁺	16–23 % (51–75)	4–11 % (13–34)	25–34 % (80–108)	11–21 % (34–68)	6–13 % (18–40)
<i>Yersinia enterocolitica</i> IgA⁺ or IgG⁺	23–35 % (75–112)	6–14 % (19–46)	11–21 % (34–68)	34–50 % (110–159)	11–19 % (35–61)
<i>Borrelia afzelii</i> IgG⁺	13–22 % (42–70)	5–11 % (15–35)	6–13 % (18–40)	11–19 % (35–61)	22–29 % (69–94)

Percentages are given in relation to all 320 serum samples included in this study. The absolute numbers of positive until positive plus borderline tested sera is given in brackets

prevalence is higher than in the winter months [30]. This might explain the increased prevalence rate of *Campylobacter*-specific antibodies in the healthy blood donor cohort in comparison to our previous studies [21, 22]. Similarly, 60–65 % of GBS patients tested positive for both *Campylobacter*-specific IgA and IgG antibodies; it therefore follows that 34–49 % (≈42 %) of GBS cases in this study are statistically associated with campylobacteriosis. Several studies have investigated the proportion of *Campylobacter*-triggered GBS and given an impression of an increase in *Campylobacter* associated GBS over time. For example, Winer et al. attributed 14 % [31], Rees et al. attributed 26 % [32], Jacobs et al. attributed 32 % [33], Hao et al. attributed 45 % [34] and our group attributed 80 % [21] of GBS cases to *Campylobacter*. This increase in the detection of seroprevalence can be attributed to improved detection methods. In this study, our data on German patients supports the findings of Hao et al. who associated 45 % of GBS cases with a prior *Campylobacter* infection in a study on a Japanese population [34] but varies from other studies which underestimated [31–33] or overestimated [21] the proportion of post-*Campylobacter* GBS. However, the varying proportion of AMAN, AMSAN and MFS cases that have been demonstrated to be associated with a prior *Campylobacter* infection relative to AIDP cases in GBS study populations [6] could be another reason for these differences in the prevalence of *Campylobacter*-specific antibodies. Future studies are required to address this thought.

Furthermore, we tested all GBS sera for *H. pylori*-, *M. pneumoniae*-, *Y. enterocolitica*-, and *B. afzelii*-reactive antibodies. The relatively high rate of double *Mycoplasma*- and *Campylobacter*-positive sera of GBS patients (23–33 %) indicates that there could be additive effects triggering autoantibodies causing GBS by sequential (or simultaneous) infections with *M. pneumoniae* and *C. jejuni*. Otherwise, there could be significant test cross-reactivity between both

as percentages and absolute numbers of double positive tested serum samples in all 320 tested patients and blood donors

bacterial species. The rate of 4 % of *Mycoplasma*-antibody positivity in *Campylobacter*-negative GBS-patients substantiates our data for *Campylobacter* seroprevalence in GBS patients, because it delivers valid data explaining the etiology of the remaining *Campylobacter*-negative GBS cases.

In contrast to that, the increased rate of double *Borrelia* and *Campylobacter* seropositive GBS patients (26–30 %) indicates an association between *Campylobacter*-triggered neuronal disease and neuroborreliosis either in antigenic interference (serodiagnostics) or even in etiology.

In the present study, we demonstrate a *Campylobacter* seroprevalence (IgA+IgG) rate of 70–78 % in RA patients. By subtracting the prevalence of *Campylobacter*-specific antibodies (16–26 %) of healthy BD, about 44–62 % (≈53 %) of RA cases are associable with *Campylobacter*. Moreover, tests to determine *H. pylori*-, *M. pneumoniae*-, *Y. enterocolitica*-, and *B. afzelii*-reactive antibodies in all the sera showed higher *Campylobacter*-specific antibodies than those of other pathogens. The association of yersiniosis and RA is well described [35, 36] and reconfirmed by the seroprevalence data of this study. The relatively low *B. afzelii* seroprevalence rate (8–20 %) as well as the low rate of double *Borrelia* and *Campylobacter* antibody-positive sera in RA patients (6 %) indicates that the subgroup of *Borrelia*-reactive arthritis interferes only to a minor degree with post-*Campylobacter* RA.

One debatable question is the contribution of *Campylobacter* caused episodes of acute gastroenteritis to the pathogenesis of IBD. Recent investigations in gnotobiotic mice demonstrated that the composition of the intestinal flora plays a pivotal role in the pathogenesis of acute campylobacteriosis. Due to their microbiota composition, mice display a natural colonization resistance against *C. jejuni* [16, 17]. Quantitative analysis of the bacterial gut flora composition revealed two- to three-fold increased *Escherichia coli* loads in intestinal ‘humanized’ mice that are susceptible to *C. jejuni* compared to resistant mice recolonized

with a murine gut flora [16, 17]. Likewise, high-elevated *E. coli* amounts increase the susceptibility to *S. enterica*-caused enteritis in mice [37–39]. Here a vicious circle starts because intestinal inflammation is associated with remarkable changes in the gut microbiota. Intestinal inflammation results in a decrease in the diversity of natural bacterial species in the gut leading to overgrowth of commensals such as *E. coli*, *Bacteroides* spp., and *Prevotella* spp. [40–44]. This dysbiosis in turn increases the susceptibility for *C. jejuni*- and *S. enterica*-caused enteritis. Additionally it was shown that *E. coli* LPS triggers TLR-4-signalling, which is a key signal for initiation and continuation of enteritis [41, 42]. Continuous inflammation is one pivotal parameter in the multifactorial pathogenesis of IBD [13, 45]. In this regard we are faced with a delicate codependency situation. On one hand, IBD patients are more susceptible to enteric pathogens [13, 45, 46], while on the other hand, recurrent episodes of acute bacterial enterocolitis trigger the manifestation of IBD in susceptible individuals [11, 12, 47]. Thus, the significantly ($p<0.001$) increased *Campylobacter*-seroprevalence in IBD patients, which ranges from 23 to 40 % (≈ 32 %), subtracting the prevalence of *Campylobacter*-specific antibodies in 16–26 % of healthy individuals (BD) in our study, supports the theory of campylobacteriosis-triggered IBD as well as the theory of an increased susceptibility for *Campylobacter* in IBD patients. Recent studies performed on rodent mice have revealed that *H. hepaticus* and *H. bilis* employ the same mechanism to trigger IBD [48]. Therefore, further studies are required to determine if a similar situation applies to other enteric pathogens.

The overall low *H. pylori*-seroprevalence rate (13–23 %) and especially the low rate of double *Helicobacter*- and *Campylobacter*-reactive sera (9–17 %) indicates that there is very little influence of cross-reactivity between both bacterial species in this study. The reasonably high rate of *Yersinia*-antibody positive sera especially among patients who were also tested *Campylobacter*-seropositive may be explained by unspecific (re-) activation of the specific intestinal immune response against an intestinal pathogen (especially in IBD) but also by antigenic interference, that would be a significant weakness in *Campylobacter* serodiagnostics. Therefore, this aspect has to be further addressed in future studies.

In conclusion, we show that antigens OMP18+P39 (for IgA) and P39 (for IgG) have larger ROC AUCs than WCL, OMP18, MOMP, PEB1, PEB2 and PEB4 antigens. Therefore, their usage in diagnostics of previous *Campylobacter* infections will produce much more reliable results. In addition, we present valid data showing that a higher proportion of post-infectious sequelae, namely, GBS, RA and IBD are triggered by *Campylobacter* spp. as compared to *H. pylori*, *M. pneumoniae*, *Y. enterocolitica*, and *Borellia* spp. However, there is evidence for codependency between *Campylobacter* infections and infections with these pathogens to trigger particular post infectious sequelae. Therefore, further studies should address how the sum of

antibodies specific for these pathogens increases the risk to trigger a particular post infectious sequel and to which extent cross-reactivity of these antibodies affects the specificity of diagnostic tests.

Acknowledgments We thank Sonja Stimpfig and Christiane Scholz for excellent technical assistance, and we are grateful to David Hunt for revising the text of the manuscript.

Financial support The authors' work was supported by the Deutsche Forschungsgemeinschaft (GR 906/13-1) and the Forschungsförderungsprogramm of the Universitätsmedizin Göttingen, Germany. This publication was funded by the Open Access support program of the Deutsche Forschungsgemeinschaft and the publication fund of the Georg August Universität Göttingen.

Potential conflicts of interest All authors report no potential conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Allos BM (1997) Association between *Campylobacter* infection and Guillain-Barre syndrome. *J Infect Dis* 176(Suppl 2):S125–S128
- Nachamkin I, Allos BM, Ho T (1998) *Campylobacter* species and Guillain-Barre syndrome. *Clin Microbiol Rev* 11(3):555–567
- Butzler JP (2004) *Campylobacter*, from obscurity to celebrity. *Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis* 10(10): 868–876
- Dasti JI, Tareen AM, Lugert R, Zautner AE, Groß U (2010) *Campylobacter jejuni*: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. *Int J Med Microbiol: IJMM* 300(4):205–211
- Zautner AE, Herrmann S, Groß U (2010) *Campylobacter jejuni*—The search for virulence-associated factors. *Arch Leb* 61(3):91–101
- Schwerer B (2002) Antibodies against gangliosides: a link between preceding infection and immunopathogenesis of Guillain-Barre syndrome. *Microbes Infect/Inst Pasteur* 4(3):373–384
- Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM (2007) *Campylobacter* reactive arthritis: a systematic review. *Semin Arthritis Rheum* 37(1):48–55
- Mortensen NP, Kuijff ML, Ang CW, Schiellerup P, Krogfelt KA, Jacobs BC, van Belkum A, Endtz HP, Bergman MP (2009) Sialylation of *Campylobacter jejuni* lipo-oligosaccharides is associated with severe gastro-enteritis and reactive arthritis. *Microbes Infect/Inst Pasteur* 11(12):988–994
- Townes JM (2010) Reactive arthritis after enteric infections in the United States: the problem of definition. *Clin Infect Dis: Off Publ Infect Dis Soc Am* 50(2):247–254
- Hannu T, Mattila L, Rautelin H, Pelkonen P, Lahdenne P, Siitonen A, Leirisalo-Repo M (2002) *Campylobacter*-triggered reactive arthritis: a population-based study. *Rheumatology* 41(3):312–318
- Garcia Rodriguez LA, Ruigomez A, Panes J (2006) Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. *Gastroenterology* 130(6):1588–1594
- Gradel KO, Nielsen HL, Schonheyder HC, Ejlersen T, Kristensen B, Nielsen H (2009) Increased short- and long-term risk of inflammatory

- bowel disease after salmonella or campylobacter gastroenteritis. *Gastroenterology* 137(2):495–501
13. Jess T, Simonsen J, Nielsen NM, Jorgensen KT, Bager P, Ethelberg S, Frisch M (2011) Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. *Gut* 60(3):318–324
 14. Riddle MS, Gutierrez RL, Verdu EF, Porter CK (2012) The chronic gastrointestinal consequences associated with campylobacter. *Curr Gastroenterol Rep* 14(5):395–405
 15. Masanta WO, Heimesaat MM, Bereswill S, Tareen AM, Lugert R, Groß U, Zautner AE (2013) Modification of intestinal microbiota and its consequences for innate immune response in the pathogenesis of campylobacteriosis. *Clin Dev Immunol* 2013:10
 16. Bereswill S, Fischer A, Plickert R, Haag LM, Otto B, Kuhl AA, Dasti JI, Zautner AE, Munoz M, Loddenkemper C, Groß U, Gobel UB, Heimesaat MM (2011) Novel murine infection models provide deep insights into the “menage a trois” of Campylobacter jejuni, microbiota and host innate immunity. *PLoS ONE* 6(6):e20953
 17. Bereswill S, Plickert R, Fischer A, Khül AA, Loddenkemper C, Batra A, Siegmund B, Göbel UB, Heimesaat MM (2011) What you eat is what you get: Novel Campylobacter models in the quadrangle relationship between nutrition, obesity, microbiota and susceptibility to infection. *Eur J Microbiol Immunol* 1(3):237–248
 18. Boswell TC, Kudesia G (1992) Serological cross-reaction between *Legionella pneumophila* and campylobacter in the indirect fluorescent antibody test. *Epidemiol Infect* 109(2):291–295
 19. Colmegna I, Cuchacovich R, Espinoza LR (2004) HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. *Clin Microbiol Rev* 17(2):348–369
 20. Corso J, Lugert R, Groß U, Zautner AE (2011) Is the Campylobacter jejuni secretory protein Cj0069 a suitable antigen for serodiagnostics? *Eur J Microbiol Immunol* 1(1):86–94
 21. Schmidt-Ott R, Schmidt H, Feldmann S, Brass F, Krone B, Groß U (2006) Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain-Barre syndrome. *Clin Vaccine Immunol: CVI* 13(7):779–783
 22. Schmidt-Ott R, Brass F, Scholz C, Werner C, Groß U (2005) Improved serodiagnosis of Campylobacter jejuni infections using recombinant antigens. *J Med Microbiol* 54(Pt 8):761–767
 23. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, Heesemann J, Hartung HP (1993) The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barre syndrome and in other neuroimmunological disorders. *Ann Neurol* 34(2):136–144
 24. Maeland JA, Bevanger L, Enge J (1993) Serological testing for campylobacteriosis with sera forwarded for Salmonella and Yersinia serology. *APMIS: Acta Pathol Microbiol Immunol Scand* 101(8):647–650
 25. Strid MA, Engberg J, Larsen LB, Begtrup K, Molbak K, Krogfelt KA (2001) Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients. *Clin Diagn Lab Immunol* 8(2):314–319
 26. Blaser MJ, Duncan DJ (1984) Human serum antibody response to Campylobacter jejuni infection as measured in an enzyme-linked immunosorbent assay. *Infect Immun* 44(2):292–298
 27. Blaser MJ, Hopkins JA, Vasil ML (1984) Campylobacter jejuni outer membrane proteins are antigenic for humans. *Infect Immun* 43(3):986–993
 28. Burnens A, Stucki U, Nicolet J, Frey J (1995) Identification and characterization of an immunogenic outer membrane protein of Campylobacter jejuni. *J Clin Microbiol* 33(11):2826–2832
 29. Pei ZH, Ellison RT 3rd, Blaser MJ (1991) Identification, purification, and characterization of major antigenic proteins of Campylobacter jejuni. *J Biol Chem* 266(25):16363–16369
 30. Sopwith W, Birtles A, Matthews M, Fox A, Gee S, Painter M, Regan M, Syed Q, Bolton E (2008) Identification of potential environmentally adapted Campylobacter jejuni strain, United Kingdom. *Emerg Infect Dis* 14(11):1769–1773
 31. Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP (1988) A prospective study of acute idiopathic neuropathy. II. Antecedent events. *J Neurol Neurosurg Psychiatry* 51(5):613–618
 32. Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barre syndrome. *N Engl J Med* 333(21):1374–1379
 33. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkass H, van der Meche FG (1996) Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. *Ann Neurol* 40(2):181–187
 34. Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, Obayashi H, Saida K (1998) Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barre syndrome with preceding Campylobacter jejuni and other identified infections. *J Neuroimmunol* 81(1–2):116–126
 35. Cover TL, Aber RC (1989) *Yersinia enterocolitica*. *N Engl J Med* 321(1):16–24
 36. Bottone EJ (1997) *Yersinia enterocolitica*: the charisma continues. *Clin Microbiol Rev* 10(2):257–276
 37. Stecher B, Chaffron S, Kappeli R, Hapfelmeier S, Friedrich S, Weber TC, Kirundi J, Suar M, McCoy KD, von Mering C, Macpherson AJ, Hardt WD (2010) Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. *PLoS Pathog* 6(1):e1000711
 38. Stecher B, Hardt WD (2011) Mechanisms controlling pathogen colonization of the gut. *Curr Opin Microbiol* 14(1):82–91
 39. Stecher B, Robbiani R, Walker AW, Westendorf AM, Barthel M, Kremer M, Chaffron S, Macpherson AJ, Buer J, Parkhill J, Dougan G, von Mering C, Hardt WD (2007) *Salmonella enterica* serovar typhimurium exploits inflammation to compete with the intestinal microbiota. *PLoS Biol* 5(10):2177–2189
 40. Heimesaat MM, Bereswill S, Fischer A, Fuchs D, Struck D, Niebergall J, Jahn HK, Dunay IR, Moter A, Gescher DM, Schumann RR, Gobel UB, Liesenfeld O (2006) Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with *Toxoplasma gondii*. *J Immunol* 177(12):8785–8795
 41. Heimesaat MM, Fischer A, Jahn HK, Niebergall J, Freudenberg M, Blaut M, Liesenfeld O, Schumann RR, Gobel UB, Bereswill S (2007) Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal *Escherichia coli*. *Gut* 56(7):941–948
 42. Heimesaat MM, Fischer A, Siegmund B, Kupz A, Niebergall J, Fuchs D, Jahn HK, Freudenberg M, Loddenkemper C, Batra A, Lehr HA, Liesenfeld O, Blaut M, Gobel UB, Schumann RR, Bereswill S (2007) Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. *PLoS ONE* 2(7):e662
 43. Wohlgenuth S, Keller S, Kertscher R, Stadion M, Haller D, Kislung S, Jahreis G, Blaut M, Loh G (2011) Intestinal steroid profiles and microbiota composition in colitic mice. *Gut Microbes* 2(3):159–166
 44. Haag LM, Fischer A, Otto B, Plickert R, Kühl AA, Gobel UB, Bereswill S, Heimesaat MM (2012) Intestinal microbiota shifts towards elevated commensal *Escherichia coli* loads abrogate colonization resistance against Campylobacter jejuni in mice. *PLoS ONE* 7(5):e35988
 45. Kalischuk LD, Buret AG (2010) A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease? *Am J Physiol Gastrointest Liver Physiol* 298(1):G1–G9
 46. Man SM, Kaakoush NO, Mitchell HM (2011) The role of bacteria and pattern-recognition receptors in Crohn’s disease. *Nat Rev Gastroenterol Hepatol* 8(3):152–168
 47. Helms M, Simonsen J, Molbak K (2006) Foodborne bacterial infection and hospitalization: a registry-based study. *Clin Infect Dis: Off Publ Infect Dis Soc Am* 42(4):498–506
 48. Hansen R, Thomson JM, Fox JG, El-Omar EM, Hold GL (2011) Could *Helicobacter* organisms cause inflammatory bowel disease? *FEMS Immunol Med Microbiol* 61(1):1–14